Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 8/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29065238 | 1.00 | CYP1A2 (0.41) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL19897431 | 0.94 | SMN1; SMN2 (0.43) | CYP1A2ACECYP2C19SMN1; SMN2 | |
| SCHEMBL19897428 | 0.94 | SMN1; SMN2 (0.43) | CYP1A2ACECYP2C19SMN1; SMN2 | |
| SCHEMBL19897439 | 0.94 | SMN1; SMN2 (0.43) | CYP1A2ACECYP2C19SMN1; SMN2 | |
| SCHEMBL2558042 | 0.83 | POLB (0.39) | LMNASMN1; SMN2 | |
| SCHEMBL351763 | 0.83 | CYP1A2 (0.40) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL15665285 | 0.83 | CYP1A2 (0.40) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL351762 | 0.83 | CYP1A2 (0.40) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL262183 | 0.81 | SLC6A1 (0.45) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL31053890 | 0.81 | CYP1A2 (0.40) | CYP1A2ACECYP2C19RENLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101180290-B | Hydogrenated benzo[c] thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-12-12 | — | — | CN | claimed |
| CN-101522670-B | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-05-23 | — | — | CN | claimed |
| CN-101203503-B | Novel thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-12-28 | — | — | CN | claimed |
| CN-101627034-A | Amino-pyridine derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD | 2010-01-13 | — | — | CN | claimed |
| CN-101522670-A | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | claimed |
| CN-101511827-A | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-19 | — | — | CN | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| CN-101203503-A | Novel thiophene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-18 | — | — | CN | claimed |
| CN-101180290-A | Hydogrenated benzo[c] thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-14 | — | — | CN | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| CN-101627034-B | amino-pyridine derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD | 2013-05-15 | — | — | CN | disclosed |
| CN-101180290-B | Hydogrenated benzo[c] thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-12-12 | — | — | CN | disclosed |
| CN-101522670-B | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-05-23 | — | — | CN | disclosed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | CYP1A2 174/4885ACE 30/4885CYP2C19 336/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CYP1A2 1715/4885ACE 29/4885CYP2C19 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.